key: cord-0764276-57uc7mfi
authors: Elsayed, Ismaeil; Meier, Benjamin; Caca, Karel; Wannhoff, Andreas
title: Potential use of a novel telemetric sensor capsule in patients with suspected gastrointestinal bleeding during the COVID-19 pandemic
date: 2021-01-13
journal: Endoscopy
DOI: 10.1055/a-1319-1496
sha: d8ed62e75e09fe560553eb76fae6c6045f885e28
doc_id: 764276
cord_uid: 57uc7mfi

nan

Upper gastrointestinal endoscopy during the COVID-19 pandemic carries a risk of disease transmission [1, 2] . The HemoPill (Ovesco Endoscopy, Tübingen, Germany) is composed of an orally administered telemetric sensor capsule that is capable of detecting blood and hematin, and a wireless receiver for data display [3 -5] . Results are expressed as the HemoPill indicator (HI). A HI value ≥ 0.8 during the first 10 minutes of the examination or ≥ 1.0 thereafter denotes a positive test result. We evaluated this sensor capsule in patients with confirmed or suspected COVID-19. Case #1 was a patient with COVID-19, congestive heart failure, and severe obesity who reported melena and had a drop of hemoglobin from 14.6 g/dL to 11.3 g/ dL. She required low-flow oxygen but was otherwise clinically stable. The maximum HI value was 1.0 after 89 minutes (▶ Fig. 1a) . Endoscopy subsequently showed a gastric ulcer with a non-bleeding visible vessel (▶ Fig. 1b) . Patient #2 suffered from dyspnea and anemia (hemoglobin 4.3 g/dL) with possible gastrointestinal bleeding. She was routinely tested for SARS-CoV-2 and isolated until receipt of her result. The COVID-19 communication ▶ Fig. 1 Images of HemoPill examination in two patients showing: a a screenshot of the HemoPill Receiver in patient #1, which revealed a maximum HI of 1.0 after 89 minutes of examination, therefore denoting a positive test result; b endoscopic image in patient #1, with a nonspurting visible vessel identified in the stomach that was treated with through-the-scope clips; c a screenshot of the HemoPill Receiver in patient #2, which revealed a negative test result; d a photograph of the HemoPill capsule, an orally administered telemetric sensor capsule capable of detecting liquid blood or hematin. maximum HI value was 0.2 (▶ Fig. 1c) . Her endoscopy, which showed no evidence of gastrointestinal bleeding, was postponed for 48 hours until receipt of negative test result. Patient #3 suffered from COVID-19 and was therefore receiving anticoagulant therapy. He underwent endoscopic retrograde cholangioscopy with papillotomy because of biliary pancreatitis; he reported a single episode of hematochezia 1 week after the endoscopy and his hemoglobin had dropped by 4.5 g/dL to 7.9 g/dL. His maximum HI value was 0.8 and no endoscopy was performed. No further episodes of bleeding were reported and the patient's hemoglobin remained stable. This sensor capsule (▶ Fig. 1 d) 

Virological assessment of hospitalized patients with COVID-2019

ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic

Novel telemetric sensor capsule for EGD urgency triage: a feasibility study

Pre-clinical study on a telemetric gastric sensor for recognition of acute upper gastrointestinal bleeding: the "HemoPill monitor

Volunteer case series of a new telemetric sensor for blood detection in the upper gastrointestinal tract: The HemoPill